gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani

Infection and Immunity
Swati BhowmickNahid Ali

Abstract

Visceral leishmaniasis is deadly if not treated, and development of a vaccine with long-term immunity remains a challenge. In this study, we showed that cationic distearoyl phosphatidylcholine (DSPC) liposomes, when used as vaccine adjuvant with the immunodominant 63-kDa glycoprotein (gp63) of Leishmania donovani promastigotes, induced significant protection against progressive visceral leishmaniasis in susceptible BALB/c mice. gp63 used without adjuvant elicited partial protection but in association with liposomes exhibited marked resistance in both the livers and spleens of the mice challenged 10 days after the last vaccination. The protective efficacy of liposomal gp63 vaccination was dose dependent, with 2.5 mug of protein showing optimal protection. The immunity conferred by this vaccine formulation was durable, as mice challenged 12 weeks after immunization were still protected, and the infection was controlled for at least 3 months postchallenge. Production of gamma interferon (IFN-gamma) and interleukin-4 (IL-4) by splenic T cells, and of serum immunoglobulin G1 (IgG1) and IgG2a following immunization, suggested that a mixed Th1/Th2 response had been induced following immunization. However, control of disease progressio...Continue Reading

References

Aug 14, 1992·Biochimica Et Biophysica Acta·M C Woodle, D D Lasic
Mar 1, 1990·Immunology Today·G Gregoriadis
Jan 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·C S Chang, K P Chang
Nov 15, 1981·Analytical Biochemistry·W WrayR Hancock
May 1, 1983·The Journal of Experimental Medicine·D A LepayZ Cohn
Jan 1, 1997·Annual Review of Immunology·S L Constant, K Bottomly
Dec 17, 1997·Biochemical and Biophysical Research Communications·T NakanishiT Mayumi
Sep 2, 1999·Journal of Controlled Release : Official Journal of the Controlled Release Society·T NakanishiT Mayumi
Jan 13, 2000·Experimental Parasitology·J A StreitM E Wilson
Mar 22, 2000·Proceedings of the National Academy of Sciences of the United States of America·L R HuangJ T Kung
Jul 6, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S GurunathanR A Seder
Jul 19, 2000·Current Opinion in Immunology·S GurunathanR A Seder
Dec 20, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S StägerP M Kaye
Apr 6, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·S MéndezD Sacks
Apr 9, 2001·Clinical Microbiology Reviews·E Handman
Jun 26, 2001·Clinical and Experimental Immunology·K MaashoH Akuffo
Nov 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·G G ChikhM P Schutze-Redelmeier
Dec 12, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J E UzonnaP Bretscher
Jan 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Isabelle MiconnetPedro Romero
Feb 19, 2002·Molecular and Biochemical Parasitology·Phalgun B JoshiW Robert McMaster
Apr 20, 2002·Current Opinion in Infectious Diseases·Carl A. Power
May 11, 2002·Nature Reviews. Immunology·Susan M KaechRaft Ahmed
Oct 3, 2002·American Journal of Clinical Dermatology·Peter C Melby
Jan 24, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xuanmao JiaoJames Wai-Kuo Shih
Sep 3, 2003·Nature Reviews. Drug Discovery·Derek T O'Hagan, Nicholas M Valiante
Oct 18, 2003·Molecular and Biochemical Parasitology·Chaoqun YaoMary E Wilson
Dec 6, 2003·The Journal of Experimental Medicine·Ben L KellyRichard M Locksley

❮ Previous
Next ❯

Citations

Sep 14, 2011·Journal of Tropical Medicine·Krystal J Evans, Lukasz Kedzierski
Mar 9, 2011·Bioinformation·Sukrat SinhaAshutosh Tripathi
Jan 30, 2010·Expert Review of Vaccines·Joana A CarvalhoGabriel A Monteiro
Dec 14, 2011·Expert Review of Vaccines·Delaram Doroud, Sima Rafati
Apr 22, 2011·Expert Review of Vaccines·Dennis ChristensenElse Marie Agger
Jul 26, 2012·Expert Review of Vaccines·Karen Smith KorsholmDennis Christensen
Jul 2, 2008·Expert Opinion on Drug Delivery·Sudipta Bhowmick, Nahid Ali
Oct 13, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Swati BhowmickNahid Ali
Oct 7, 2009·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Eric Dumonteil
Nov 18, 2011·Molecular Biology International·Angana Ghoshal, Chitra Mandal
Aug 8, 2013·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Alexis García, Juan B De Sanctis
May 28, 2011·International Immunopharmacology·Rajeev Nagill, Sukhbir Kaur
Feb 26, 2016·Expert Review of Vaccines·Sima RafatiFarnaz Zahedifard
Dec 5, 2017·Therapeutic Advances in Vaccines·Anis AskarizadehAli Badiee
Jan 10, 2020·Expert Opinion on Drug Delivery·Anis AskarizadehAli Khamesipour
Dec 29, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Pragya ChandrakarSusanta Kar
Apr 4, 2017·Journal of Immunology Research·Juliana Seger LinkVanete Thomaz Soccol

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.